Humana Inc. (NYSE:HUM) Shares Sold by Raiffeisen Bank International AG

Key Points

• Raiffeisen Bank International AG reduced its stake in Humana Inc. by 15.6%, owning 6,486 shares worth approximately $1.72 million after selling 1,200 shares in Q1.
• Several institutional investors, including American Century Companies Inc. and Prudential PLC, either increased their stakes or established new positions in Humana, with institutional ownership now at 92.38%.
• Humana reported a missed earnings estimate with EPS of $6.27 versus the consensus of $6.32, while its revenue of $32.39 billion exceeded analyst expectations.

Raiffeisen Bank International AG trimmed its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 15.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,486 shares of the insurance provider's stock after selling 1,200 shares during the quarter. Raiffeisen Bank International AG's holdings in Humana were worth $1,716,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of HUM. Blair William & Co. IL grew its position in shares of Humana by 11.6% in the 1st quarter. Blair William & Co. IL now owns 4,614 shares of the insurance provider's stock worth $1,221,000 after buying an additional 481 shares during the last quarter. Banco Santander S.A. purchased a new stake in shares of Humana during the first quarter worth about $245,000. OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Humana during the first quarter valued at about $696,000. Shufro Rose & Co. LLC purchased a new position in shares of Humana in the 1st quarter valued at approximately $210,000. Finally, Sound View Wealth Advisors Group LLC boosted its stake in Humana by 5.8% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,154 shares of the insurance provider's stock worth $305,000 after purchasing an additional 63 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HUM shares. Bank of America decreased their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a report on Tuesday, June 17th. Piper Sandler cut their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Morgan Stanley reduced their target price on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research note on Thursday, July 31st. Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target on the stock. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $281.62.

Humana Price Performance

NYSE HUM traded down $0.66 during trading hours on Thursday, reaching $255.96. The company's stock had a trading volume of 850,384 shares, compared to its average volume of 2,015,970. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72. The firm has a market capitalization of $30.78 billion, a price-to-earnings ratio of 19.64, a P/E/G ratio of 1.51 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The company's 50-day moving average is $236.69 and its two-hundred day moving average is $254.69.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The business's revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.96 earnings per share. On average, equities analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.